首页 > 市场调查报告书 > 製药

再生医学细胞疗法

市场调查报告书

商品编码

1532346

自动化和封闭式细胞疗法的全球市场

Global Automated and Closed Cell Therapy Market

出版日期: 2024年08月06日 | 出版商:

BCC Research | 英文 112 Pages | 订单完成后即时交付

价格

简介目录图表

全球自动化和封闭式细胞治疗市场规模预计年终2024 年的 18 亿美元增加到 2029 年底的 53 亿美元，预测期内复合年增长率为 23.9%。

北美地区预计将从 2024 年的 7.522 亿美元成长到 2029年终的21 亿美元，复合年增长率为 22.3%。此外，欧洲地区预计将从2024年的5.391亿美元成长到2029年底的15亿美元，复合年增长率为22.9%。

本报告调查了全球自动化和封闭式细胞治疗市场，并提供了市场概况、市场影响因素和市场机会分析、新兴技术和技术发展趋势、市场规模趋势和预测，并按各个细分市场和地区进行了主要企业总结。

细分细分
全球自动化和封闭细胞治疗市场：按自动化类型
半自动
全自动
全球自动化和封闭细胞治疗市场：按细胞类型
CAR-T细胞
干细胞
其他的
全球自动化和闭式细胞治疗市场：按应用分类
市场规模/预测
临床
商业的
地域分布
全球自动化和封闭细胞治疗市场：按地区
市场规模/预测
北美洲
欧洲
亚太地区
其他领域

第六章竞争讯息

竞争格局
合伙
投资金筹措
专利分析

第七章自动化和闭式细胞治疗市场的永续性

自动化和封闭式细胞治疗产业的永续性
了解 ESG资料
环境绩效
社会表现
管治绩效
BCC 的结论

第8章附录

调查方法
来源
缩写词
公司简介
ADVA BIOTECHNOLOGY
BIOSPHERIX LTD.
CELLARES
DANAHER CORP.
FRESENIUS SE & CO. KGAA
LONZA
MILTENYI BIOTEC
SARTORIUS AG
TERUMO CORP.
HERMO FISHER SCIENTIFIC INC.

简介目录图表

Product Code: BIO258A

The global market for automated and closed cell therapy is expected to grow from $1.8 billion in 2024 and is projected to reach $5.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 23.9% during the forecast period of 2024 to 2029.

The North American market for automated and closed cell therapy is expected to grow from $752.2 million in 2024 and is projected to reach $2.1 billion by the end of 2029, at a CAGR of 22.3% during the forecast period of 2024 to 2029.

The European market for automated and closed cell therapy is expected to grow from $539.1 million in 2024 and is projected to reach $1.5 billion by the end of 2029, at a CAGR of 22.9% during the forecast period of 2024 to 2029.

Report Scope:

The report highlights the current and future market potential of automated and closed cell therapy systems and a detailed analysis of the market drivers, restraints, and opportunities. The report also covers market projections for 2029, a competitive environment, patent, and product analysis. The report provides market estimates and forecasts for automated and closed cell therapy based on automation, cell type, application, and region. The market is segmented into CAR-T cells, stem cells, and other cell types based on cell type. The market is categorized as clinical and commercial based on the application type. The market is segmented into semi-automated and fully automated based on the type of automation. The semi-automated systems are further segmented based on workflow into apheresis, expansion, fill-finish, separation, and others. The report includes company profiles of the key industry players with detailed information about their business segments, financials, product portfolios, and recent developments. The report does not cover automated systems for basic operations such as pipetting or mixing.

By geography, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). Regional analysis is further broken down by country as follows: North America-the U.S., Canada, and Mexico; Europe-Germany, the U.K., France, Italy, Spain, and the Rest of Europe; Asia-Pacific-China, Japan, India, South Korea, Australia, and the Rest of Asia-Pacific. For market estimates, data has been provided for 2021 and 2022 as the historic years, 2023 as the base year, and forecast through 2029.

Report Includes:

43 data tables and 46 additional tables
An overview of the current and future global markets for automated and closed cell therapy
Analyses of global market trends, with market revenue data (sales figures) for 2021-2023, estimates for 2024 and projected CAGRs through 2029
Estimates of the market size and revenue forecasts, with market share analysis based on the automation type, cell type, application, and region
Discussions of the market dynamics, opportunities and challenges, as well as emerging technologies
Overview of the sustainability and ESG trends, with emphasis on the ESG practices followed by leading companies, their ESG rankings and consumer attitudes
Competitive intelligence, including companies' market shares, recent M&A activity, and venture funding.
Profiles of the leading companies, including Danaher Corp., Thermo Fischer Scientific Inc., Lonza, and Sartorius AG

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Insights

Chapter 2 Market Overview

Overview
Types of Cell Therapy
Applications of Cell Therapy
Regenerative Medicine
Cancer
Autoimmune Disorders

Chapter 3 Market Dynamics

Market Dynamics Snapshot
Market Drivers
Point-of-Care Manufacturing in CAR-T Therapies
Growing Demand for Regenerative Medicine
Market Restraints
High Costs and Integration Challenges
Regulatory Uncertainties
Market Opportunities
Increasing Startups in Cell Therapy Manufacturing
Scalable Platforms

Chapter 4 Emerging Technologies and Developments

Introduction
Real-Time Monitoring (RTM) of Operations
Off-the-Shelf Cell Therapies
Miniaturization of Cell Therapy Systems

Chapter 5 Market Segmentation Analysis

Segmentation Breakdown
Global Automated and Closed Cell Therapy Market by Automation Type
Semi-Automated Cell Therapy
Fully Automated Cell Therapy
Global Automated and Closed Cell Therapy Market by Cell Type
CAR-T Cells
Stem Cells
Other Cell Types
Global Automated and Closed Cell Therapy Market by Application
Market Size and Forecast
Clinical
Commercial
Geographic Breakdown
Global Market for Automated and Closed Cell Therapy by Region
Market Size and Forecast
North America
Europe
Asia-Pacific
Rest of the World (RoW)

Chapter 6 Competitive Intelligence

Competitive Landscape
Partnerships
Investments and Funding
Patent Analysis

Chapter 7 Sustainability in the Automated and Closed Cell Therapy Market

Introduction
Sustainability in the Automated and Closed Cell Therapy Industry
Understanding the ESG Data
Environmental Performance
Social Performance
Governance Performance
Concluding Remarks from BCC

Chapter 8 Appendix

Methodology
Sources
Acronyms
Company Profiles
ADVA BIOTECHNOLOGY
BIOSPHERIX LTD.
CELLARES
DANAHER CORP.
FRESENIUS SE & CO. KGAA
LONZA
MILTENYI BIOTEC
SARTORIUS AG
TERUMO CORP.
THERMO FISHER SCIENTIFIC INC.

简介目录图表

List of Tables

Summary Table : Global Market for Automated and Closed Cell Therapy, by Region, Through 2029
Table 1 : Classification of Stem Cells
Table 2 : Comparison Between Autologous and Allogeneic Therapeutics
Table 3 : Companies with Off-the-Shelf Therapeutics Pipeline
Table 4 : Differences between Semi-Automation and Full Automation in Cell Therapy
Table 5 : Global Market for Automated and Closed Cell Therapy, by Automation Type, Through 2029
Table 6 : Select Semi-Automated Cell Therapy Systems
Table 7 : Global Market for Semi-Automated Cell Therapy, by Region, Through 2029
Table 8 : Global Market for Semi-Automated Cell Therapy, by Workflow, Through 2029
Table 9 : Global Market for Automated and Closed Apheresis, by Region, Through 2029
Table 10 : Global Market for Automated and Closed Expansion, by Region, Through 2029
Table 11 : Global Market for Automated and Closed Fill-Finish, by Region, Through 2029
Table 12 : Global Market for Automated and Closed Separation, by Region, Through 2029
Table 13 : Global Market for Other Automated and Closed Workflows, by Region, Through 2029
Table 14 : Global Market for Fully Automated Cell Therapy, by Region, Through 2029
Table 15 : Global Market for Automated and Closed Cell Therapy, by Cell Type, Through 2029
Table 16 : FDA-Approved CAR-T Cell Therapies
Table 17 : Global Market for Automated and Closed CAR-T Cell Therapy, by Region, Through 2029
Table 18 : Global Market for Automated and Closed Stem Cell Therapy, by Region, Through 2029
Table 19 : Global Market for Automated and Closed Other Cell Therapies, by Region, Through 2029
Table 20 : Global Market for Automated and Closed Cell Therapy, by Application, Through 2029
Table 21 : Global Market for Clinical Automated and Closed Cell Therapy, by Region, Through 2029
Table 22 : Global Market for Commercial Automated and Closed Cell Therapy, by Region, Through 2029
Table 23 : Global Market for Automated and Closed Cell Therapy, by Region, Through 2029
Table 24 : North American Market for Automated and Closed Cell Therapy, by Country, Through 2029
Table 25 : North American Market for Automated and Closed Cell Therapy, by Automation Type, Through 2029
Table 26 : North American Market for Semi-automated Automated and Closed Cell Therapy, by Workflow, Through 2029
Table 27 : North American Market for Automated and Closed Cell Therapy, by Cell Type, Through 2029
Table 28 : North American Market for Automated and Closed Cell Therapy, by Application, Through 2029
Table 29 : European Market for Automated and Closed Cell Therapy, by Country, Through 2029
Table 30 : European Market for Automated and Closed Cell Therapy, by Automation Type, Through 2029
Table 31 : European Market for Semi-Automated Automated and Closed Cell Therapy, by Workflow, Through 2029
Table 32 : European Market for Automated and Closed Cell Therapy, by Cell Type, Through 2029
Table 33 : European Market for Automated and Closed Cell Therapy, by Application, Through 2029
Table 34 : Asia-Pacific Market for Automated and Closed Cell Therapy, by Country, Through 2029
Table 35 : Asia-Pacific Market for Automated and Closed Cell Therapy, by Automation Type, Through 2029
Table 36 : Asia-Pacific Market for Semi-Automated and Closed Cell Therapy, by Workflow, Through 2029
Table 37 : Asia-Pacific Market for Automated and Closed Cell Therapy, by Cell Type, Through 2029
Table 38 : Asia-Pacific Market for Automated and Closed Cell Therapy, by Application, Through 2029
Table 39 : RoW Market for Automated and Closed Cell Therapy, by Automation Type, Through 2029
Table 40 : RoW Market for Semi-Automated and Closed Cell Therapy, by Workflow, Through 2029
Table 41 : RoW Market for Automated and Closed Cell Therapy, by Cell Type, Through 2029
Table 42 : RoW Market for Automated and Closed Cell Therapy, by Application, Through 2029
Table 43 : Top Automated and Closed Cell Therapy Companies, 2023
Table 44 : Select Strategic Alliances in the Automated and Closed Cell Therapy Industry, 2022-2024
Table 45 : Major Funding Activities in the Automated and Closed Cell Therapy Industry, 2022-2024
Table 46 : Active Patents of the Key Competitor Companies, 2022-2024
Table 47 : ESG Rankings for Major Automated and Closed Cell Therapy, 2024*
Table 48 : ESG: Environmental Overview
Table 49 : ESG: Social Overview
Table 50 : ESG: Governance Overview
Table 51 : Report Sources
Table 52 : Glossary of Terms Used in the Automated and Closed Cell Therapy Market
Table 53 : Adva Biotechnology: Company Snapshot
Table 54 : Adva Biotechnology: Product Portfolio
Table 55 : Adva Biotechnology: News/Key Developments, 2024
Table 56 : Biospherix Ltd.: Company Snapshot
Table 57 : Biospherix Ltd.: Product Portfolio
Table 58 : Biospherix Ltd.: News/Key Developments, 2022
Table 59 : Cellares: Company Snapshot
Table 60 : Cellares: Product Portfolio
Table 61 : Cellares: News/Key Developments, 2024
Table 62 : Danaher Corp.: Company Snapshot
Table 63 : Danaher Corp.: Financial Performance, FY 2022 and 2023
Table 64 : Danaher Corp.: Product Portfolio
Table 65 : Danaher Corp.: News/Key Developments, 2024
Table 66 : Fresenius SE & Co. KGAA: Company Snapshot
Table 67 : Fresenius SE & Co. KGAA: Financial Performance, FY 2022 and 2023
Table 68 : Fresenius SE & Co. KGaA: Product Portfolio
Table 69 : Fresenius SE & Co. KGAA: News/Key Developments, 2023
Table 70 : Lonza: Company Snapshot
Table 71 : Lonza: Financial Performance, FY 2022 and 2023
Table 72 : Lonza: Product Portfolio
Table 73 : Lonza: News/Key Developments, 2022
Table 74 : Miltenyi Biotec: Company Snapshot
Table 75 : Miltenyi Biotec: Product Portfolio
Table 76 : Miltenyi Biotec: News/Key Developments, 2024
Table 77 : Sartorius AG: Company Snapshot
Table 78 : Sartorius AG: Financial Performance, FY 2022 and 2023
Table 79 : Sartorius AG: Product Portfolio
Table 80 : Sartorius AG: News/Key Developments, 2024
Table 81 : Terumo Corp.: Company Snapshot
Table 82 : Terumo Corp.: Financial Performance, FY 2022 and 2023
Table 83 : Terumo Corp.: Product Portfolio
Table 84 : Terumo Corp.: News/Key Developments, 2024
Table 85 : Thermo Fisher Scientific Inc.: Company Snapshot
Table 86 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
Table 87 : Thermo Fisher Scientific Inc.: Product Portfolio
Table 88 : Thermo Fisher Scientific Inc.: News/Key Developments, 2024

List of Figures

Summary Figure : Global Market Shares of Automated and Closed Cell Therapy, by Region, 2023
Figure 1 : Types of Cells Used in Cell Therapies
Figure 2 : Benefits of Automated and Closed Cell Therapy Manufacturing
Figure 3 : Market Dynamics of Global Automated and Closed Cell Therapy Market
Figure 4 : Workflow Involved in the Production of CAR-T Therapies
Figure 5 : Emerging Technologies in the Automated and Closed Cell Therapy Market
Figure 6 : Global Market Shares of Automated and Closed Cell Therapy, by Automation Type, 2023
Figure 7 : Global Market for Semi-Automated Cell Therapy, by Region, 2021-2029
Figure 8 : Global Market for Fully Automated Cell Therapy, by Region, 2021-2029
Figure 9 : Global Market Shares of Automated and Closed Cell Therapy, by Cell Type, 2023
Figure 10 : Global Market for Automated and Closed CAR-T Cell Therapy, 2021-2029
Figure 11 : Global Market for Automated and Closed CAR-T Cell Therapy, by Region, 2021-2029
Figure 12 : Global Market for Automated and Closed Stem Cell Therapy, 2021-2029
Figure 13 : Global Market for Automated and Closed Stem Cell Therapy, by Region, 2021-2029
Figure 14 : Global Market for Automated and Closed Other Cell Therapies, 2021-2029
Figure 15 : Global Market for Automated and Closed Other Cell Therapies, by Region, 2021-2029
Figure 16 : Global Market Shares of Automated and Closed Cell Therapy, by Application, 2023
Figure 17 : Global Market for Clinical Automated and Closed Cell Therapy, 2021-2029
Figure 18 : Global Market for Commercial Automated and Closed Cell Therapy, 2021-2029
Figure 19 : Global Market Shares of Automated and Closed Cell Therapy, by Region, 2023
Figure 20 : Global Market for Automated and Closed Cell Therapy, by Region, 2021-2029
Figure 21 : North American Market Shares of Automated and Closed Cell Therapy, by Country, 2023
Figure 22 : U.S. Market for Automated and Closed Cell Therapy, 2021-2029
Figure 23 : Canadian Market for Automated and Closed Cell Therapy, 2021-2029
Figure 24 : Mexican Market for Automated and Closed Cell Therapy, 2021-2029
Figure 25 : European Market Shares of Automated and Closed Cell Therapy, by Country, 2023
Figure 26 : German Market for Automated and Closed Cell Therapy, 2021-2029
Figure 27 : French Market for Automated and Closed Cell Therapy, 2021-2029
Figure 28 : Italian Market for Automated and Closed Cell Therapy, 2021-2029
Figure 29 : Spanish Market for Automated and Closed Cell Therapy, 2021-2029
Figure 30 : U.K. Market for Automated and Closed Cell Therapy, 2021-2029
Figure 31 : Rest of Europe Market for Automated and Closed Cell Therapy, 2021-2029
Figure 32 : Asia-Pacific Market Shares of Automated and Closed Cell Therapy, by Country, 2023
Figure 33 : Chinese Market for Automated and Closed Cell Therapy, 2021-2029
Figure 34 : Japanese Market for Automated and Closed Cell Therapy, 2021-2029
Figure 35 : Indian Market for Automated and Closed Cell Therapy, 2021-2029
Figure 36 : Australian Market for Automated and Closed Cell Therapy, 2021-2029
Figure 37 : South Korean Market for Automated and Closed Cell Therapy, 2021-2029
Figure 38 : Rest of Asia-Pacific Market for Automated and Closed Cell Therapy, 2021-2029
Figure 39 : Snapshot of the ESG Pillars
Figure 40 : Advantages of ESG for Companies
Figure 41 : ESG Goals of Automated and Closed Cell Therapy Companies
Figure 42 : Danaher Corp.: Revenue Share, by Business Unit, FY 2023
Figure 43 : Danaher Corp.: Revenue Share, by Country/Region, FY 2023
Figure 44 : Fresenius SE & Co. KGAA: Revenue Share, by Business Unit, FY 2023
Figure 45 : Fresenius SE & Co. KGAA: Revenue Share, by Country/Region, FY 2023
Figure 46 : Lonza: Revenue Share, by Business Unit, FY 2023
Figure 47 : Lonza: Revenue Share, by Country/Region, FY 2023
Figure 48 : Sartorius AG: Revenue Share, by Business Unit, FY 2023
Figure 49 : Sartorius AG: Revenue Share, by Country/Region, FY 2023
Figure 50 : Terumo Corp.: Revenue Share, by Business Unit, FY 2023
Figure 51 : Terumo Corp.: Revenue Share, by Country/Region, FY 2023
Figure 52 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2023
Figure 53 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2023